Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety.

Details

Language :

English

ISSN :

00257974

Volume :

100

Issue :

23

Database :

Complementary Index

Journal :

Medicine

Publication Type :

Academic Journal

Accession number :

151444911

Full Text :

https://doi.org/10.1097/MD.0000000000025709